What changed for Schizophrenia
A plain English summary of what recently moved in the public data Voxsanity tracks for Schizophrenia. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 301 to 311 (+10)
- Late-stage (Phase 3) trials 29 to 30 (+1)
- Trials on record 3,157 to 3,196 (+39)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Schizophrenia in July 2026. Voxsanity tracks 12 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 194 trials tracked for Schizophrenia that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT01945333 · results posted 17 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT01945333) enrolled 115 people in total across four groups. Participants were divided based on two things: which type of computer-based brain programme they were assigned to ("Brain Basics" or "Brain Training"), and whether they had difficulty matching tones — a measure of a particular auditory skill — before the trial started ("Impaired" or "Intact" tone matchers). The trial was primarily testing whether it was practical to enrol people, randomly assign them to a group, and keep them engaged through to the end — in other w...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04092686 · results posted 18 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04092686) enrolled 464 participants across three groups: one group received a placebo (a dummy treatment with no active ingredient), one received a 75 mg dose of SEP-363856, and one received a 100 mg dose of SEP-363856. The trial ran for 6 weeks and was primarily measuring changes in schizophrenia symptom severity using two standardised rating tools completed by clinicians — the PANSS (a 30-question interview covering a range of symptoms) and the CGI-S (a single question rating overall illness severity). Around 365 of the...
-
NCT05211947 · results posted 8 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,356 people, all of whom received a drug called iclepertin at a dose of 10 mg. Of those who started, 632 people completed the trial and 724 did not finish. The trial's main focus was on tracking unwanted health events (called "treatment emergent adverse events") that occurred while people were taking the medication. It also looked at two secondary measures: changes in the severity of participants' condition using a rated scale, and changes in haemoglobin levels (a measure of red blood cells in the blood). The report...
-
NCT05899348 · results posted 18 March 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 people in a single group called "iTEST," of whom 52 completed the study and 8 did not finish. The trial was measuring a concept called **introspective accuracy** — that is, how well people could judge their own performance on memory and thinking tasks. Specifically, participants each day estimated how many items they got right on two tasks (recognising emotions in photos of faces, and remembering a list of words), and the difference between their guess and their actual score was recorded. The trial also tracked how...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05380583 · results posted 27 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05380583) involved family members or carers of people experiencing early psychosis. There were four groups tracked: 21 carers who received a program called CRAFT-EP alongside usual treatment, 22 carers who received usual treatment only, and two smaller subgroups made up of the family members' loved ones who had psychosis (4 in the CRAFT-EP group and 18 in the usual treatment group). The trial was measuring how carers' depression, anxiety, and relationship happiness changed over time. The reported data shows the following...
-
NCT04013555 · results posted 11 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04013555) tested a supplement called N-acetylcysteine (NAC) compared to a placebo (an inactive dummy treatment) in people who also received tryptophan (an amino acid). The trial used a "crossover" design, meaning participants received both the NAC and the placebo at different times. Around 36–70 people started the trial across two challenge days, with roughly 51–58 completing both sessions. The trial was measuring levels of certain chemicals in the blood — kynurenine and kynurenic acid (both natural substances produced whe...
-
NCT03238326 · results posted 4 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03238326) involved participants who were already taking part in an earlier study of brexpiprazole (a medication used for psychiatric conditions). The trial had two parts: a short four-week "conversion period," in which 14 new ("de novo") participants joined, and a longer open-label period of about 25 months, in which participants were divided into groups based on what they had previously received — those who had been on brexpiprazole, those who had been on aripiprazole, those who had been on placebo, and the new de novo gr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03383874 · results posted 19 December 2025
According to the results reported on ClinicalTrials.gov, this trial involved 67 people in total — 36 were given a placebo (a dummy treatment with no active ingredient) and 31 were given a probiotic supplement called Probio-Tec BG-VCap-6.5. The trial was looking at whether taking a probiotic could affect the rate of psychiatric relapse, meaning whether participants needed to be re-admitted to hospital for psychiatric symptoms after having been discharged at least two weeks earlier. Not everyone completed the study — 20 out of 36 people in the placebo group finished, compared to 25 out of 31 in...
-
NCT01964404 · results posted 9 December 2025
According to the results reported on ClinicalTrials.gov, this trial involved people across several groups: those with Cannabis Use Disorder (CUD) only, those with schizophrenia only, those with both conditions (called "dual diagnosis" or SCZ-CUD), and healthy volunteers used as a comparison group. In total, 263 people started the pre-randomisation phase across all groups. The trial was measuring how the brain's reward circuitry — particularly a region called the nucleus accumbens — responded during brain scans (fMRI), both at rest and during a money-reward task. Participants in the CUD and SCZ...
-
NCT06061952 · results posted 18 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06061952) looked at a programme called Customised Adherence Enhancement for Schizophrenia (CAE-S) — a structured support intervention aimed at helping people with schizophrenia take their medication as prescribed. The trial enrolled 36 people in total: 19 were assigned to the CAE-S programme and 17 received an enhanced version of their usual care (called eTAU). By the end of the 12-week study, 16 people in the CAE-S group and 13 in the usual-care group had completed it. The reported data shows that, among those in the CAE...
-
NCT04779177 · results posted 12 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 26 adults who each took a 42 mg dose of lumateperone (a tablet) once daily for five days. Twenty-one participants completed the study, and five did not finish. The trial was not testing whether the medicine treated a condition — instead, it was measuring **pharmacokinetics**, which is simply the science of tracking how a drug moves through the body: how quickly it is absorbed, how high its levels rise in the blood, and how long it takes to leave the body. The reported data shows several measurements taken from blood...
-
NCT04846868 · results posted 5 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04846868) enrolled 620 adults with schizophrenia — 312 received a daily 10 mg dose of an investigational medicine called iclepertin, and 308 received a placebo (a dummy pill with no active ingredient). The trial ran for 26 weeks and was primarily measuring whether iclepertin affected thinking and cognitive (mental processing) abilities compared to the placebo. A smaller sub-group of 48 participants also took part in an eye safety assessment. The reported data shows that the main outcome — a standardised thinking and cogni...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05368558 · results posted 20 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05368558) studied a medication called cariprazine in people with schizophrenia. The trial ran in several stages: a double-blind period (where neither participants nor doctors knew who received which treatment), a blinded extension period, and follow-up phases. In the main double-blind period, 34 people took part — 16 received a placebo (a dummy treatment with no active ingredient), 5 received cariprazine at 3 mg, and 13 received cariprazine at 6 mg. The trial's main goals were to count how many participants experienced adv...
-
NCT06002958 · results posted 18 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06002958) involved two groups of participants: 20 healthcare providers (called "FEP Providers") and 32 clients receiving care for first-episode psychosis (called "FEP Clients") — 52 people in total. All 52 who started the study completed it. The trial was looking at a digital platform called Horyzons, and measured things like how providers and clients experienced using it, as well as changes in feelings of loneliness and sense of social support among clients. The reported data shows that for the provider group, structured...
-
NCT04820309 · results posted 17 September 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 566 people, all of whom received a treatment called KarXT. The trial was an open-label, long-term safety study — meaning there was no comparison group — and its main purpose was to track what unwanted medical events (called adverse events) occurred while people were taking the drug over time. Secondary measures looked at serious adverse events, how many people stopped taking the drug due to adverse events, and changes in schizophrenia symptom scores over 52 weeks. Of the 566 people who started, 277 completed the study...
-
NCT03481049 · results posted 11 August 2025
According to the results reported on ClinicalTrials.gov, this trial looked at three different approaches to a type of incentive-based support program called Contingency Management (CM) — where people receive rewards for meeting certain goals — aimed at reducing alcohol use in people with serious mental health conditions. A total of 158 people were randomly assigned to one of three groups: a "Usual CM" group (53 people), a "High-Magnitude CM" group (54 people), and a "Shaping CM" group (51 people). An additional 234 people were enrolled but not randomly assigned to a group. Of those who were ra...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00373672 · results posted 5 August 2025
According to the results reported on ClinicalTrials.gov, this trial involved 58 people in total, split evenly into two groups of 29. One group received a treatment referred to as "ARM" alongside an antipsychotic drug (APD), while the other group received a placebo ("PLC") alongside an antipsychotic drug. All 58 participants completed the study — none dropped out. The trial was measuring cognition, specifically a type of attention and mental focus tested using something called the AX-Continuous Performance Task (AX-CPT). This test looks at how well a person can hold information in mind over a s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03034356 · results posted 14 July 2025
According to the results reported on ClinicalTrials.gov, this trial looked at whether the medication levetiracetam had any effect on brain function in participants compared to a placebo (a dummy treatment with no active ingredient). It used a "crossover" design, meaning each person took both the real medication and the placebo at different times, in a randomised order, with a rest period in between. A total of 41 people enrolled across the two groups at the start. Due to dropouts at various stages, 25 people (11 in one group and 14 in the other) completed the full trial. The reported data sho...
-
NCT05643196 · results posted 30 May 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a technique called Pulsed Low-Intensity Focused Ultrasound (PLIFUS) — a non-invasive method that uses sound waves directed at a specific area deep in the brain. Ten people took part in total, split into two groups of five. It was a "crossover" trial, meaning everyone received both the real PLIFUS treatment and a sham (a fake version designed to look and feel the same) at different points in the study. The trial was measuring whether PLIFUS changed activity in a particular brain region (the Globus Pallidus Interna), a...
-
NCT06787781 · results posted 27 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 15 people, all of whom completed the study with no drop-outs. All 15 participants were in a single group receiving Alpha Lipoic Acid (ALA), a naturally occurring compound. The trial was measuring a range of blood test results — including cholesterol, blood sugar, liver function, kidney function, and heart rhythm — as well as the severity of schizophrenia symptoms using a standardised rating tool called the PANSS scale (a questionnaire that scores symptom severity from 30 to 210, where higher numbers indicate more seve...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05623228 · results posted 5 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05623228) enrolled 35 participants in total, spread across eight therapy groups ranging in size from 2 to 8 people. The trial was measuring several things in people who took part in different therapy programmes: cognitive functions (such as memory and problem-solving), psychiatric symptoms, how well participants were able to carry out everyday activities, and their sense of personal recovery. Most participants completed the study across two follow-up periods, with only a small number — three people in total across both tim...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01569659 · results posted 28 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 67 people in total, split into two groups: 34 people received a standard dose of a medication called lurasidone, and 33 received a higher dose of lurasidone. The trial was studying symptoms of schizophrenia, specifically looking at what are called "positive symptoms" — things like hallucinations or unusual beliefs — using a structured rating tool known as the PANSS (Positive and Negative Symptom Scale). On this scale, trained clinicians interview patients and rate 30 different symptoms; higher scores indicate more sev...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05207982 · results posted 14 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05207982) enrolled 10 people in total — 5 classified as "Patients" and 5 classified as "Supporting Persons" (such as a carer or family member). All 10 participants completed the study with no drop-outs. The trial was measuring changes in body weight over time, with measurements taken at the start of the study, each week during the study period, at the end of the study, and at a follow-up point. The reported data shows individual weight changes (measured in pounds) for each participant across the two groups. For the Patien...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05136690 · results posted 29 November 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 13 healthy participants and 25 people with mild-to-moderate schizophrenia (SZ). All 13 healthy participants completed both study periods, while 20 of the 25 SZ participants completed both periods (one left before Period 2 began, and four did not finish Period 2). The trial was measuring brain signals recorded by EEG — specifically how consistently and strongly the brain responds to certain sound patterns — and whether wearing a nicotine patch changed those signals compared to a dummy (placebo) patch. The reported dat...
-
NCT04659174 · results posted 28 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04659174) enrolled 152 people with schizophrenia across two groups — 68 in Arm A and 84 in Arm B — who all received a medicine called KarXT. The trial ran for up to 52 weeks and was mainly set up to track how many participants experienced adverse events (unwanted medical occurrences that appeared or got worse after starting the study drug). A relatively small number of participants completed the study — 19 in Arm A and 16 in Arm B — with the majority not completing it, though the reasons were not broken down in the data pr...
-
NCT04001114 · results posted 26 September 2024
According to the results reported on ClinicalTrials.gov, this trial involved two groups of adult smokers: 18 people who had a diagnosis of schizophrenia and 13 people who did not. Of those who started, 17 and 9 participants respectively completed the study. The trial was measuring how people responded to cigarettes that contained almost no nicotine — specifically looking at how much carbon monoxide (a marker of how much smoke was inhaled) was in their breath, how well they could tell the difference between a regular cigarette and a very-low-nicotine cigarette, how their smoking behaviour chang...
-
NCT03818256 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03818256) enrolled 71 adults in total — 35 received a daily dose of miricorilant (600 mg) and 36 received a placebo (a dummy pill with no active ingredient). The trial was measuring changes in body weight over 12 weeks, as well as tracking unwanted health events that occurred during the study. A smaller number of participants completed the full trial: 27 in the miricorilant group and 28 in the placebo group, with 8 people in each group not finishing. The reported data shows that, after 12 weeks, body weight changed by an...
-
NCT03995368 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this study enrolled 93 people across three groups: 28 people with schizophrenia, 34 people with a traumatic brain injury (TBI), and 31 healthy volunteers (people without either condition). Not everyone finished — 26, 23, and 26 people respectively completed the study. The trial was measuring how the brain processes sound and visual information using a technique called EEG (a painless test that records electrical activity in the brain), and also looked at thinking and memory skills, social understanding, and how well people were getting o...
-
NCT02918370 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02918370) enrolled 75 people in total — 36 in the aripiprazole group and 39 in the placebo group. A placebo is a dummy treatment with no active ingredient, used for comparison. The trial was measuring changes in alcohol use, specifically looking at the number of drinks people consumed on the days they drank. This was tracked using a tool called the Timeline Followback (TLFB), which asks participants to recall their recent drinking. The key measurement was how much this figure changed between the start of the trial and week...
-
NCT03669640 · results posted 12 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03669640) looked at symptoms of schizophrenia — particularly a group of symptoms called "negative symptoms," which can include things like low motivation, reduced emotional expression, and social withdrawal. The trial was split into two parts: Part A tested the investigational treatment on its own (monotherapy) compared to a placebo (a dummy treatment with no active ingredient), and Part B tested it as an add-on to existing medication at three different doses (45 mg, 150 mg, and 300 mg) compared to a placebo. In total, 131...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 194 reported results for Schizophrenia
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, schizophrenia currently attracts a very large amount of public research investment from the United States government, and that investment has remained broadly steady from one year to the next. For patients, this signals that schizophrenia is treated as a serious and ongoing research priority at an international level. A sustained and substantial funding base generall...
See the full Schizophrenia page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.